PT - JOURNAL ARTICLE AU - Linda Aurpibul AU - Patumrat Sripan AU - Wason Paklak AU - Arunrat Tangmunkongvorakul AU - Amaraporn Rerkasem AU - Kittipan Rerkasem AU - Kriengkrai Srithanaviboonchai TI - Characteristics, clinical outcomes, and mortality of older adults living with HIV receiving antiretroviral treatment in the sub-urban and rural areas of northern Thailand AID - 10.1101/2022.06.27.22276956 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.27.22276956 4099 - http://medrxiv.org/content/early/2022/06/27/2022.06.27.22276956.short 4100 - http://medrxiv.org/content/early/2022/06/27/2022.06.27.22276956.full AB - Since the introduction of antiretroviral treatment (ART), people living with HIV worldwide live into older age. This study described the characteristics, clinical outcomes, and mortality of older adults living with HIV (OALHIV) receiving ART from the National AIDS program in northern Thailand. Participants aged ≥ 50 years were recruited from the HIV clinics in 12 community hospitals. Data were obtained from medical records and face-to-face interviews. In 2015, 362 OALHIV were enrolled; their median (interquartile range) age and ART duration were 57 years (54-61), and 8.8 years (6.4-11.2), respectively. At study entry, 174 (48.1%) had CD4 counts ≥ 500 cells/mm3; 357 of 358 (99.6%) with available HIV RNA results were virologic-suppressed. At the year 5 follow-up, 39 died, 11 were transferred to other hospitals, 3 were lost to follow-up, and 40 did not contribute data for this analysis, but remained in care. Among the 269 who appeared, 149 (55%) had CD4 counts ≥ 500 cells/mm3, and 227/229 tested (99%) were virologic-suppressed. The probability of 5-year overall survival (OS) was 89.2% (95% confidence interval, CI 85.4-92.1%). A significantly low 5-year OS (66%) was observed in OALHIV with CD4 counts < 200 cells/mm3 at study entry. The most common cause of death was organ failures in 11 (28%), followed by malignancies in 8 (21%), infections in 5 (13%), mental health-related conditions in 2 (5%), and unknown in 13 (33%). In OALHIV with stable HIV outcomes, monitoring of organ functions, cancer surveillance, and mental health screening are warranted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKS: Chiang Mai University The funder play no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board at Research Institute for Health Sciences, Chiang Mai UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.